Roland M. du Bois
- An earlier and more confident diagnosis of idiopathic pulmonary fibrosisBy Roland M. du BoisRoland M. du Bois
- A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancerBy Carlo Vancheri and Roland M. du BoisCarlo Vancheri*Dept of Clinical and Molecular Biomedicine, University of Catania, Catania, ItalyRoland M. du Bois#National Heart & Lung Institute, Imperial College, London, UK
- Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway FibrosisBy Luca Richeldi, Harold R. Collard, Roland M. du Bois, Gisli Jenkins, Martin Kolb, Toby M. Maher, Ganesh Raghu, Carlo Vancheri and Geoffrey J. LaurentLuca Richeldi1Centre for Rare Lung Diseases, University of Modena and Reggio Emilia, ModenaHarold R. Collard2University of California, San Francisco, CARoland M. du Bois3Imperial College London, LondonGisli Jenkins4University of Nottingham, NottinghamMartin Kolb5Dept of Respiratory Medicine, Pathology and Molecular Medicine, McMaster University, Hamilton, CanadaToby M. Maher6Interstitial Lung Disease Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College London, LondonGanesh Raghu7Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA, USACarlo Vancheri8Dept of Internal Medicine, University of Catania, Catania, ItalyGeoffrey J. Laurent9University of Western Australia, All authors were members of the scientific committee of the 17th ICLAF meeting, Perth, Australia10University College London, London, UK
- Efficacy of BIBF 1120 in patients with IPF is dose-dependent: Results from the TOMORROW trialBy Ulrich Costabel, Luca Richeldi, Moises Selman, Dong Soon Kim, Kevin K. Brown, Kevin R. Flaherty, Paul W. Noble, Ganesh Raghu, Michèle Brun, Abhya Gupta, Matthias Klueglich, Nolwenn Juhel and Roland M. du BoisUlrich Costabel1Ruhrlandklinik and Medical Faculty, University of Duisburg-Essen, Essen, GermanyLuca Richeldi2Center for Rare Lung Disease, University of Modena and Reggio Emilia, Modena, ItalyMoises Selman3Instituto Nacional de Enfermedades Respiratorias, “Ismael Cosio Villegas”, México, MexicoDong Soon Kim4Division of Pulmonary and Critical Care Medicine, Asan Medical Center, Seoul, KoreaKevin K. Brown5Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, National Jewish Health, Denver, United StatesKevin R. Flaherty6Department of Internal Medicine, Pulmonary and Critical Care Division, University of Michigan, Ann Arbor, United StatesPaul W. Noble7Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, United StatesGanesh Raghu8Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, United StatesMichèle Brun9Boehringer Ingelheim France S.A.S., Boehringer Ingelheim, Reims, FranceAbhya Gupta10Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim, Biberach, GermanyMatthias Klueglich10Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim, Biberach, GermanyNolwenn Juhel9Boehringer Ingelheim France S.A.S., Boehringer Ingelheim, Reims, FranceRoland M. du Bois11National Heart & Lung Institute, Imperial College, London, United Kingdom
- Effect of baseline FVC on preservation of lung function with BIBF 1120: Results from the TOMORROW trialBy Luca Richeldi, Ulrich Costabel, Moises Selman, Dong Soon Kim, Kevin R. Flaherty, Paul W. Noble, Ganesh Raghu, Arata Azuma, Michèle Brun, Abhya Gupta, Matthias Klueglich, Nolwenn Juhel and Roland M. du BoisLuca Richeldi1Center for Rare Luna Disease, University of Modena and Reggio Emilia, Modena, ItalyUlrich Costabel2Ruhrlandklinik and Medical Faculty, University of Duisburg-Essen, Essen, GermanyMoises Selman3Instituto Nacional de Enfermedades Respiratorias, “Ismael Cosio Villegas”, Mèxico, MexicoDong Soon Kim4Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan, Seoul, KoreaKevin R. Flaherty5Department of Internal Medicine, Pulmonary and Critical Care Division, University of Michigan, Ann Arbor, United StatesPaul W. Noble6Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, United StatesGanesh Raghu7Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, United StatesArata Azuma8Division of Respiratory Medicine, Infection and Oncology, Nippon Medical School, Tokyo, JapanMichèle Brun9Boehringer Ingelheim France S.A.S., Boehringer Ingelheim, Reims, FranceAbhya Gupta10Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim, Biberach, GermanyMatthias Klueglich10Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim, Biberach, GermanyNolwenn Juhel9Boehringer Ingelheim France S.A.S., Boehringer Ingelheim, Reims, FranceRoland M. du Bois11National Heart & Lung Institute, Imperial College, London, United Kingdom
- 6-minute walk distance as a predictor of outcome in idiopathic pulmonary fibrosisBy Roland M. du BoisRoland M. du BoisImperial College London, London, UK
- 6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosisBy Roland M. du Bois, Carlo Albera, Williamson Z. Bradford, Ulrich Costabel, Jonathan A. Leff, Paul W. Noble, Steven A. Sahn, Dominique Valeyre, Derek Weycker and Talmadge E. KingRoland M. du Bois1Imperial College London, London, UKCarlo Albera2University of Turin, Turin, ItalyWilliamson Z. Bradford3InterMune Inc., Brisbane, CA, USAUlrich Costabel4Ruhrlandklinik, Essen, GermanyJonathan A. Leff3InterMune Inc., Brisbane, CA, USAPaul W. Noble5Cedars Sinai Medical Center, Los Angeles, CA, USASteven A. Sahn6Medical University of South Carolina, Charleston, SC, USADominique Valeyre7Assistance Publique-Hôpitaux, Paris, FranceDerek Weycker8Policy Analysis Inc., Brookline, MA, USATalmadge E. King Jr9University of California, San Francisco, CA, USA
- Mapping the future for pulmonary fibrosisBy Luca Richeldi, Harold R. Collard, Roland M. du Bois, Gisli Jenkins, Martin Kolb, Toby M. Maher, Ganesh Raghu, Carlo Vancheri and Geoffrey J LaurentArticle | Published in 2013 in European Respiratory JournalLuca Richeldi*University of Modena and Reggio Emilia (Italy)Harold R. Collard#University of California San Francisco (USA)Roland M. du Bois¶Imperial College London (UK)Gisli Jenkins+University of Nottingham (UK)Martin Kolb§McMaster University (Canada)Toby M. MaherfRoyal Brompton Hospital and Imperial College London (UK)Ganesh Raghu**University of Washington (USA)Carlo Vancheri##University of Catania (Italy)Geoffrey J Laurent¶¶University of Western Australia (Australia) and University College London (UK)++All Authors were members of the scientific committee of the 17th ICLAF meeting
- Late-breaking abstract: Pirfenidone (PFD) effect on morbidity and mortality in patients with idiopathic pulmonary fibrosis (IPF)By Paul W. Noble, Carlo Albera, Williamson Z. Bradford, Ulrich Costabel, Roland M. du Bois, Robert S. Fishman, Ian Glaspole, Marilyn K. Glassberg, Lisa Lancaster, David Lederer, Jonathan A. Leff, Steven D. Nathan, Carlos A. Pereira, Jeffrey J. Swigris, Dominique Valeyre and Talmadge E. KingPaul W. Noble1Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA,Carlo Albera2Department of Clinical and Biological Sciences, University of Turin, Turin, ItalyWilliamson Z. Bradford3Research & Development, InterMune Inc., Brisbane, CA,Ulrich Costabel4Department of Pneumology, Ruhrlandklinik, Essen, GermanyRoland M. du Bois5Respiratory Medicine, Imperial College, London, United KingdomRobert S. Fishman3Research & Development, InterMune Inc., Brisbane, CA,Ian Glaspole6Interstitial Lung Disease, Alfred Hospital, Melbourne, AustraliaMarilyn K. Glassberg7Pulmonology, University of Miami Miller School of Medicine, Miami, FL,Lisa Lancaster8Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN,David Lederer9Department of Clinical Medicine, Columbia University Medical Center, New York, NY,Jonathan A. Leff3Research & Development, InterMune Inc., Brisbane, CA,Steven D. Nathan10Advanced Lung Disease & Transplant Program, Inova Fairfax Hospital, Falls Church, VA,Carlos A. Pereira11Department of Medicine, Paulista School of Medicine, São Paulo, BrazilJeffrey J. Swigris12Department of Medicine, National Jewish Health, Denver, CO,Dominique Valeyre13Service de Pneumologie, Assistance Publique-Hôpitaux de Paris, Hôpital Avicenne, Bobginy, FranceTalmadge E. King Jr14Department of Medicine, University of California, San Francisco School of Medicine, San Francisco, CA,
- Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosisBy Brett Ley, Williamson Z. Bradford, Derek Weycker, Eric Vittinghoff, Roland M. du Bois and Harold R. CollardArticle | Published in 2015 in European Respiratory JournalBrett Ley1Dept of Medicine, University of California San Francisco, San Francisco, CA, USAWilliamson Z. Bradford2InterMune Inc., Brisbane, CA, USADerek Weycker3Policy Analysis Inc. (PAI), Brookline, MA, USAEric Vittinghoff4Dept of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USARoland M. du Bois5Imperial College, London, UKHarold R. Collard1Dept of Medicine, University of California San Francisco, San Francisco, CA, USA
- Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosisBy Brett Ley, Williamson Z. Bradford, Derek Weycker, Eric Vittinghoff, Roland M. du Bois and Harold R. CollardBrett Ley1Dept of Medicine, University of California San Francisco, San Francisco, CA, USAWilliamson Z. Bradford2InterMune Inc., Brisbane, CA, USADerek Weycker3Policy Analysis Inc. (PAI), Brookline, MA, USAEric Vittinghoff4Dept of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USARoland M. du Bois5Imperial College, London, UKHarold R. Collard1Dept of Medicine, University of California San Francisco, San Francisco, CA, USA
- An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune featuresBy Aryeh Fischer, Katerina M. Antoniou, Kevin K. Brown, Jacques Cadranel, Tamera J. Corte, Roland M. du Bois, Joyce S. Lee, Kevin O. Leslie, David A. Lynch, Eric L. Matteson, Marta Mosca, Imre Noth, Luca Richeldi, Mary E. Strek, Jeffrey J. Swigris, Athol U. Wells, Sterling G. West, Harold R. Collard and Vincent CottinArticle | Published in 2015 in European Respiratory JournalAryeh Fischer1Dept of Medicine, University of Colorado School of Medicine, Denver, CO, USA17Task force chair18Members of the writing group of the task forceKaterina M. Antoniou2Thoracic Medicine, University of Crete, Heraklion, GreeceKevin K. Brown3Dept of Medicine, National Jewish Health, Denver, CO, USAJacques Cadranel4Pneumologie, Hopital Tenon, Paris, FranceTamera J. Corte5The Aldred Hospital, Melbourne, Australia18Members of the writing group of the task forceRoland M. du Bois6Interstitial Lung Disease Unit, Dept of Occupational Medicine, Royal Brompton Hospital, London, UKJoyce S. Lee7Medicine, University of California San Francisco, San Francisco, CA, USA18Members of the writing group of the task forceKevin O. Leslie8Pathology, Mayo Clinic, Scottsdale, AZ, USADavid A. Lynch9Dept of Radiology, National Jewish Health, Denver, CO, USAEric L. Matteson10Division of Rheumatology, Mayo College of Medicine, Rochester, MN, USAMarta Mosca11University of Pisa, Pisa, ItalyImre Noth12Medicine, University of Chicago, Chicago, IL, USALuca Richeldi13Southampton General Hospital, Southampton, UKMary E. Strek12Medicine, University of Chicago, Chicago, IL, USA18Members of the writing group of the task forceJeffrey J. Swigris3Dept of Medicine, National Jewish Health, Denver, CO, USA18Members of the writing group of the task forceAthol U. Wells14Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UKSterling G. West15University of Colorado School of Medicine, Aurora, CO, USAHarold R. Collard7Medicine, University of California San Francisco, San Francisco, CA, USA18Members of the writing group of the task force19Task force vice-chairs, and contributed equally to this manuscriptVincent Cottin16Service de Pneumologie, Hopital L. Pradel, Lyon, France18Members of the writing group of the task force19Task force vice-chairs, and contributed equally to this manuscript
- An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune featuresBy Aryeh Fischer, Katerina M. Antoniou, Kevin K. Brown, Jacques Cadranel, Tamera J. Corte, Roland M. du Bois, Joyce S. Lee, Kevin O. Leslie, David A. Lynch, Eric L. Matteson, Marta Mosca, Imre Noth, Luca Richeldi, Mary E. Strek, Jeffrey J. Swigris, Athol U. Wells, Sterling G. West, Harold R. Collard and Vincent CottinAryeh Fischer1Dept of Medicine, University of Colorado School of Medicine, Denver, CO, USA17Task force chair18Members of the writing group of the task forceKaterina M. Antoniou2Thoracic Medicine, University of Crete, Heraklion, GreeceKevin K. Brown3Dept of Medicine, National Jewish Health, Denver, CO, USAJacques Cadranel4Pneumologie, Hopital Tenon, Paris, FranceTamera J. Corte5The Aldred Hospital, Melbourne, Australia18Members of the writing group of the task forceRoland M. du Bois6Interstitial Lung Disease Unit, Dept of Occupational Medicine, Royal Brompton Hospital, London, UKJoyce S. Lee7Medicine, University of California San Francisco, San Francisco, CA, USA18Members of the writing group of the task forceKevin O. Leslie8Pathology, Mayo Clinic, Scottsdale, AZ, USADavid A. Lynch9Dept of Radiology, National Jewish Health, Denver, CO, USAEric L. Matteson10Division of Rheumatology, Mayo College of Medicine, Rochester, MN, USAMarta Mosca11University of Pisa, Pisa, ItalyImre Noth12Medicine, University of Chicago, Chicago, IL, USALuca Richeldi13Southampton General Hospital, Southampton, UKMary E. Strek12Medicine, University of Chicago, Chicago, IL, USA18Members of the writing group of the task forceJeffrey J. Swigris3Dept of Medicine, National Jewish Health, Denver, CO, USA18Members of the writing group of the task forceAthol U. Wells14Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UKSterling G. West15University of Colorado School of Medicine, Aurora, CO, USAHarold R. Collard7Medicine, University of California San Francisco, San Francisco, CA, USA18Members of the writing group of the task force19Task force vice-chairs, and contributed equally to this manuscriptVincent Cottin16Service de Pneumologie, Hopital L. Pradel, Lyon, France18Members of the writing group of the task force19Task force vice-chairs, and contributed equally to this manuscript
- Effect of pirfenidone on treatment-emergent (TE) all-cause mortality (ACM) in patients with idiopathic pulmonary fibrosis (IPF): Pooled data analysis from ASCEND and CAPACITYBy Steven D. Nathan, Carlo Albera, Williamson Z. Bradford, Ulrich Costabel, Roland M. du Bois, Elizabeth A. Fagan, Ian Glaspole, Marilyn K. Glassberg, David Kardatzke, Talmadge E. King, Klaus-Uwe Kirchgaessler, Lisa H. Lancaster, David J. Lederer, Carlos A. Pereira, Jeffrey J. Swigris, Dominique Valeyre and Paul W. NobleSteven D. Nathan1Lung Transplant Program, Inova Fairfax Hospital, Falls Church, VA United StatesCarlo Albera2Clinical and Biological Sciences, University of Turin, Turin, ItalyWilliamson Z. Bradford3Intermune, Brisbane, CA United StatesUlrich Costabel4Pneumology and Allergy, Ruhrlandklinik, Essen, GermanyRoland M. du Bois5Respiratory Medicine, Imperial College, London, United KingdomElizabeth A. Fagan3Intermune, Brisbane, CA United StatesIan Glaspole6Interstitial Lung Disease Unit, Alfred Hospital and Monash University, Melbourne, AustraliaMarilyn K. Glassberg7Medicine and Surgery, University of Miami Miller School of Medicine, Miami, FL United StatesDavid Kardatzke3Intermune, Brisbane, CA United StatesTalmadge E. King Jr.8Medicine, University of California - San Francisco, San Francisco, CA United StatesKlaus-Uwe Kirchgaessler9Roche, Basel, SwitzerlandLisa H. Lancaster10Medicine, Vanderbilt University Medical Center, Nahville, TN United StatesDavid J. Lederer11Lung Transplant Program, Columbia University, New York, United StatesCarlos A. Pereira12Paulista School of Medicine, Federal University of São Paulo, São Paulo, BrazilJeffrey J. Swigris13Medicine, National Jewish Health, Denver, CO United StatesDominique Valeyre14Assistance Publique-Hôpitaux de Paris, Avicenne University, Bobigny, FrancePaul W. Noble15Medicine, Cedars-Sinai Hospital, Los Angeles, CA United States
- Effect of baseline corticosteroid medication on reduction in FVC decline with nintedanibBy Vincent Cottin, Huiping Li, Fabrizio Luppi, Florence Le Maulf, Rozsa Schlenker-Herceg, Susanne Stowasser and Roland M. Du BoisVincent Cottin1Louis Pradel Hospital, University of Lyon, Lyon, FranceHuiping Li2Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Shanghai, ChinaFabrizio Luppi3Center for Rare Lung Diseases, University Hospital of Modena, Modena, ItalyFlorence Le Maulf4Statistics, Boehringer Ingelheim France S.A.S., Reims, FranceRozsa Schlenker-Herceg5Respiratory, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT United StatesSusanne Stowasser6Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, GermanyRoland M. Du Bois7Imperial College, Imperial College, London, United Kingdom
- Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trialsBy Paul W. Noble, Carlo Albera, Williamson Z. Bradford, Ulrich Costabel, Roland M. du Bois, Elizabeth A. Fagan, Robert S. Fishman, Ian Glaspole, Marilyn K. Glassberg, Lisa Lancaster, David J. Lederer, Jonathan A. Leff, Steven D. Nathan, Carlos A. Pereira, Jeffrey J. Swigris, Dominique Valeyre and Talmadge E. KingArticle | Published in 2015 in European Respiratory JournalPaul W. Noble1Cedars-Sinai Medical Center, Los Angeles, CA, USACarlo Albera2University of Turin, Turin, ItalyWilliamson Z. Bradford3InterMune Inc., Brisbane, CA, USAUlrich Costabel4Ruhrlandklinik, University of Duisburg-Essen, Essen, GermanyRoland M. du Bois5Imperial College, London, UKElizabeth A. Fagan3InterMune Inc., Brisbane, CA, USARobert S. Fishman3InterMune Inc., Brisbane, CA, USAIan Glaspole6Alfred Hospital and Monash University, Melbourne, AustraliaMarilyn K. Glassberg7University of Miami Miller School of Medicine, Miami, FL, USALisa Lancaster8Vanderbilt University Medical Center, Nashville, TN, USADavid J. Lederer9Columbia University Medical Center, New York, NY, USAJonathan A. Leff3InterMune Inc., Brisbane, CA, USASteven D. Nathan10Inova Fairfax Hospital, Falls Church, VA, USACarlos A. Pereira11Paulista School of Medicine, Federal University of São Paulo, São Paulo, BrazilJeffrey J. Swigris12National Jewish Health, Denver, CO, USADominique Valeyre13Assistance Publique-Hôpitaux de Paris, Avicenne University Hospital, Bobigny, FranceTalmadge E. King Jr14University of California, San Francisco, San Francisco, CA, USA
- Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trialsBy Paul W. Noble, Carlo Albera, Williamson Z. Bradford, Ulrich Costabel, Roland M. du Bois, Elizabeth A. Fagan, Robert S. Fishman, Ian Glaspole, Marilyn K. Glassberg, Lisa Lancaster, David J. Lederer, Jonathan A. Leff, Steven D. Nathan, Carlos A. Pereira, Jeffrey J. Swigris, Dominique Valeyre and Talmadge E. KingPaul W. Noble1Cedars-Sinai Medical Center, Los Angeles, CA, USACarlo Albera2University of Turin, Turin, ItalyWilliamson Z. Bradford3InterMune Inc., Brisbane, CA, USAUlrich Costabel4Ruhrlandklinik, University of Duisburg-Essen, Essen, GermanyRoland M. du Bois5Imperial College, London, UKElizabeth A. Fagan3InterMune Inc., Brisbane, CA, USARobert S. Fishman3InterMune Inc., Brisbane, CA, USAIan Glaspole6Alfred Hospital and Monash University, Melbourne, AustraliaMarilyn K. Glassberg7University of Miami Miller School of Medicine, Miami, FL, USALisa Lancaster8Vanderbilt University Medical Center, Nashville, TN, USADavid J. Lederer9Columbia University Medical Center, New York, NY, USAJonathan A. Leff3InterMune Inc., Brisbane, CA, USASteven D. Nathan10Inova Fairfax Hospital, Falls Church, VA, USACarlos A. Pereira11Paulista School of Medicine, Federal University of São Paulo, São Paulo, BrazilJeffrey J. Swigris12National Jewish Health, Denver, CO, USADominique Valeyre13Assistance Publique-Hôpitaux de Paris, Avicenne University Hospital, Bobigny, FranceTalmadge E. King Jr14University of California, San Francisco, San Francisco, CA, USA
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.